ASCO American Society of Clinical Oncology

A precision medicine approach to cancer therapeutics is a biomarker-driven strategy with a laser focus on delivering therapies to the right patients at the right time. This is why predictive biomarker testing has become the basis for selecting appropriate precision therapies for cancer patients. It has helped to transform cancer treatment, which has evolved dramatically over the past 25 years.

We have brought precision medicine capabilities to community sites, empowering them to be an end-to-end solution for our clients. We do so with innovations like Oncomine Solutions, our in-house, high-speed genomic profiling solutions. Oncomine Solutions enable sponsors to solve many of the most common issues faced by precision medicine therapeutics development while allowing for elevated global data into genomic profiling for better study feasibility and site strategy.

Oncomine™ Solutions — the latest technology for fast-profiling and next-generation sequencing of key biomarkers and comprehensive genomic profiling — provides molecular insights to inform the most critical decisions with speed and accuracy.

NGS also allows drug developers to discover new biomarkers, screen patients for selection in clinical trials, develop companion diagnostics, and develop personalized treatment plans. The ability to better reach patients also aids in easing the burdens of the trial, making participation more manageable for patients who may be very ill. Time is precious for these patients. The right NGS solution allows sponsors to accelerate their programs—ultimately getting patients to treatment earlier and keeping patient-centricity at the center of their trial strategy.